Phase II Trial of Temozolomide in Patients With Cisplatin-Refractory Germ Cell Tumors
OBJECTIVES: I. Determine the efficacy of temozolomide in patients with cisplatin refractory
metastatic germ cell tumors. II. Determine the safety of this treatment in these patients.
OUTLINE: Patients receive oral temozolomide on days 1-5. Treatment repeats every 28 days for
a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study over 25 months.
Interventional
Primary Purpose: Treatment
Robert J. Motzer, MD
Study Chair
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
00-010
NCT00006043
February 2000
November 2001
Name | Location |
---|---|
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |